常用口服降糖药的药物基因组学研究进展  

Research Progress in Pharmacogenomics of Major Oral Antidiabetic Agents

作　　者：刘谋泽[1,2,3] 何发忠[1,2] 陈长仁[1,2] 张伟[1,2] 

机构地区：[1]中南大学湘雅医院临床药理研究所,湖南长沙410008 [2]中南大学临床药理研究所遗传药理学湖南省重点实验室,湖南长沙410078 [3]中南大学湘雅二医院药学部,湖南长沙410011

出　　处：《药学进展》2017年第2期101-109,共9页Progress in Pharmaceutical Sciences

基　　金：国家重点研究发展计划(No.2016YFC0905000);国家高技术研究发展计划"863"项目(No.2012AA02A518);国家自然科学基金(No.81522048;No.81573511;No.81273595);中南大学创新驱动项目(No.2016CX024)

摘　　要：近年来,中国2型糖尿病(T2DM)发病率呈快速增长趋势。T2DM是一种慢性代谢性疾病,涉及全身各个系统,甚至可能引起严重的并发症。大多数T2DM患者需长期口服降糖药物。口服降糖药的药物基因组学研究可指导个体化治疗,改善疗效,降低用药成本,减少不良反应和并发症风险,已成为当前研究的热点。综述常用口服降糖药药效学和药代动力学参数的相关基因多态性研究进展,为更加合理、有效地进行糖尿病临床个体化治疗提供参考。In recent years, the incidence of type 2 diabetes（T2DM） in China increased rapidly. T2 DM is a chronic metabolic disease involving many organ systems, and may cause serious complications. Most T2 DM patients need long-term therapy with oral hypoglycemic drugs. Study on the pharmacogenomics of oral hypoglycemic agents, a hotspot in current research, can guide individualized therapy, improve drug efficacy, lower treatment cost and reduce the risk of adverse reactions and complications. This paper reviewed the research advances in polymorphisms of genes involved in pharmacokinetics and pharmacodynamics pathways of commonly used oral hypoglycemic agents, providing references for more rational and effective individualized treatment of diabetes.

关 键 词：2型糖尿病 口服降糖药 药物基因组 精准医疗 

分 类 号：R977.15[医药卫生—药品]